HAVCR2 and acute myeloid leukemia: In testing the inhibitory effect of anti-TIM-3 mAbs on proliferation of human AML in an in vitro system, we found that anti-TIM-3 mAbs (0.5 μg/100 μl) was sufficient to interfere with the leukemic cells' proliferation, while the other concentrations didn't show a marked effect on cell survival.